In This Article:
J.P. Morgan analyst Lisa C. Gill, with a Neutral rating, updated estimates for Agilon Health, Inc. (NYSE:AGL) following fourth-quarter results posted last month.
Last month, the company reported a fourth-quarter 2024 adjusted EPS of $(0.26), missing the consensus estimate of $(0.23). However, sales for the quarter totaled $1.52 billion, which is in line with expectations.
The analyst’s revised estimates reflect an updated outlook on AGL’s recovery timeline based on management’s recent commentary.
With 2025 expected to be a year of transition, the company aims to address specific challenges while navigating another year of high trends, positioning itself to achieve its targets for 2026/2027, adds the analyst.
The analyst estimates revenue of $1.502 billion (vs. $1.503 billion consensus) and adjusted EBITDA of $16 million (in line with consensus) in the first quarter of FY25.
For FY25, Gill revised the revenue estimate to $5.926 billion (vs. $5.928 billion consensus) from $6.453 billion earlier while adjusted EBITDA loss estimate remains unchanged at $77 million (vs. consensus loss of $78 million).
For FY26, the analyst updated the revenue estimate to $6.594 billion (vs. consensus mean of $6.665 billion) from $7.319 billion prior and adjusted EBITDA loss estimate changes to $23 million (vs. consensus loss of $22 million) from loss of $10 million prior.
Investors can gain exposure to the stock via Fidelity Disruptive Medicine ETF (NASDAQ:FMED) and SPDR S&P Health Care Services ETF (NYSE:XHS).
Price Action: AGL shares are down 0.48% at $4.18 at the last check Tuesday.
Read Next:
Image via Shutterstock.
Latest Ratings for AGL
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 2021 | Deutsche Bank | Maintains | Buy | |
| Nov 2021 | SVB Leerink | Maintains | Outperform | |
| Oct 2021 | Jefferies | Initiates Coverage On | Buy |
View More Analyst Ratings for AGL
View the Latest Analyst Ratings
UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets.
Get the latest stock analysis from Benzinga?
This article Agilon Health Adjusts To Recovery Phase, Analyst Is Cautious On Near-Term Fundamentals originally appeared on Benzinga.com
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.